Be The Match BioTherapies Strengthens Partnership with Magenta Therapeutics
Organization announces second investment in Magenta with participation in Series C financing round
Amy Ronneberg, president of Be The Match BioTherapies, appointed to Magenta’s Board of Directors
MINNEAPOLIS, Minn., and CAMBRIDGE, Mass., April 9, 2018 – Be The Match BioTherapies®, an organization offering solutions for companies developing and delivering cellular therapies, today announced that it has made its second equity investment in Magenta Therapeutics, a biotechnology company developing novel therapeutics to bring the curative power of bone marrow transplant to more patients. In addition, Be The Match BioTherapies announced that Amy Ronneberg, the organization’s president, has been appointed to Magenta’s Board of Directors.
“Magenta has been working to revolutionize blood and marrow transplantation in order to extend the potentially curative benefits of transplant to more patients, including those with autoimmune disease, blood cancers and genetic diseases,” said Amy Ronneberg, president of Be The Match BioTherapies. “As an organization committed to helping companies deliver life-saving cell therapies to patients with difficult diseases, we are delighted to strengthen our partnership with Magenta and to continue to support the company’s discovery and clinical development efforts. I look forward to guiding the company, as a member of its Board of Directors, to unleash the full potential of blood and marrow transplantation for patients in need.”
Last May, Be The Match BioTherapies announced its participation in Magenta’s Series B financing round and launched a strategic partnership to support the company’s efforts to address significant needs across all aspects of transplant medicine. The collaboration between Be The Match BioTherapies and Magenta leverages a wide range of Be The Match BioTherapies’ assets and services, including an extensive network of transplant centers and cord blood banks, as well as expertise in research protocols, payer policy and patient education development.
“Be The Match BioTherapies, a patient-driven organization with deep expertise in cellular therapy, is an important partner for Magenta,” said Jason Gardner, D.Phil., chief executive officer, president and co-founder, Magenta Therapeutics. “We are pleased to have their continued support and experience as we advance our pipeline and accelerate our efforts to transform transplant medicine.”